Registry for Intra-Operative Radiotherapy in Early Stage Breast Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective registry study enrolls women with early stage breast cancer undergoing intraoperative radiotherapy (IORT) during breast-conserving surgery. The aim is to validate the long-term effectiveness and safety of IORT by assessing patient outcomes, including complications, disease recurrences, and survival rates. The registry will compare these outcomes with traditional whole breast radiation therapy, filling a critical gap in existing data on IORT. This initiative is part of a broader effort to enhance breast cancer care at Providence Saint John's Health Center.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Clinical stage Tis, T1, or T2(≤ 3cm), N0, M0 (AJCC Classification)
* Unifocal Disease
* Candidate for breast-conserving surgery
* Recommended treatment by multidisciplinary team

Exclusion Criteria:

* Clinical stage T3-4, N1-3, M1
* Multifocal disease

Where it's running

• John Wayne Cancer Institute, Providence Saint John's Health Center
  Santa Monica, California, United States Recruiting

Study contacts

• Principal investigator: Janie Grumley, MD — John Wayne Cancer Institute, Providence Saint John's Health Center
• Study coordinator: Janie Grumley, MD
• Email: janie.grumley@providence.org
• Phone: (310) 582-7100

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized treatment for breast cancer using new drug agents

  This study is testing new drug combinations with standard chemotherapy to see which treatments work best for different types of breast cancer based on the specific characteristics of each patient's tumor.

  Recruiting at 32 sites Phase 2 QuantumLeap Healthcare Collaborative · Birmingham, Alabama and 41 other locations · NCT01042379

• Improved Facial Skin Quality After VYC-12L for Breast Cancer Survivors

  This study tests whether intradermal injections of VYC-12L can improve facial skin quality and quality of life in adults who have completed breast cancer treatment.

  Recruiting Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia · Murcia, Murcia · NCT07917117

• Breast cancer subtypes and outcomes in Colombian women

  This study looks back at medical records of women with breast cancer to see how different molecular subtypes relate to survival and recurrence in a single Colombian hospital.

  Recruiting Fundación Santa Fe de Bogota · Bogotá, Bogota D.C. · NCT07856225

• One-week versus three-week partial breast irradiation for early-stage breast cancer

  This trial tests whether a shorter one-week partial breast irradiation plan is not worse than a three-week plan for women after breast-conserving surgery.

  Recruiting Fudan University · Shanghai · NCT07832279

• Culmerciclib with endocrine therapy before surgery for early HER2-negative hormone receptor-positive breast cancer

  This trial tests whether adding culmerciclib to an aromatase inhibitor before surgery helps women with certain early breast cancers better shrink tumors than an aromatase inhibitor alone.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07796880

• Multimodal psychosomatic symptom care for breast cancer: personalized acupuncture care guided by shared decision-making

  This study tests whether personalized acupuncture options (manual acupuncture, ear acupuncture, or both) can help women with breast cancer who have anxiety, sleep problems, or fatigue, compared to routine nursing care.

  Recruiting at 3 sites First Teaching Hospital of Tianjin University of Traditional Chinese Medicine · Tianjin and 2 other locations · NCT07763587

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.